J&J's Mixed Phase III Data For Esketamine Highlight Challenges In Resistant Depression

J&J released data from the first two Phase III trials testing esketamine in patients with treatment-resistant depression, but only one study met the primary efficacy endpoint.

magnetic resonance image (MRI) of the brain human

Johnson & Johnson holds big expectations for esketamine in treatment-resistant depression, but reported mixed efficacy data from the first two Phase III trials at the American Psychiatric Association annual meeting, highlighting some of the challenges for new drugs in the space.

Only one of the two trials met the primary efficacy endpoint, while the other showed a meaningful, but not statistically...